December 2009

Contents

Editorial

• Volume 10 Number 11/12 November/December 2009

Treatment alerts

• Tibotec issues Dear Doctor letter in Europe concerning severe etravirine reactions: three case reports

Conference reports

• 12th European AIDS Society Conference (EACS) 11-14 November 2009, Cologne

• EACS releases three updated management guidelines (December 2009)

• 11th International Workshop on Adverse Drug Reactions and Comorbidities in HIV (IWADR) 26-28 October 2009, Philadelphia

• Intermuscular tissue is decreased in HIV infection

• High incidence and risk factors for diabetes in French cohort

• Gender and race differences in lipodystrophy symptoms

• Lipodystrophy is common in children from three European cohorts

• Visceral adipose tissue returns to baseline after stopping therapeutic intervention with rHGH

• Reduced levels of vitamin D in patients taking efavirenz

• Association between inflammation and sleep apnea in the MACS cohort

• Sports supplements impact on serum creatinine and eGFR markers of renal function

• 9th AIDS Vaccine Conference 19-22 October 2009, Paris

• Thai HIV Vaccine Trial results presented and published

• 49th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12-15 September 2009, San Francisco

• Smoking masks the long-term benefits of HAART on lung function

• Recent ARVs and the blood/brain barrier: CSF drug concentrations of darunavir/r and raltegravir

• Raltegravir body composition study: 48-week DEXA results

• Alcohol and marijuana may reduce drug levels of atazanavir and efavirenz

• Other drug interaction studies at ICAAC

• 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town

• Early infant diagnosis

• Difficulties with implementation

• Infant outcomes

• Improved neurodevelopmental outcomes

• Treating children exposed to single dose nevirapine for PMTCT

• Using a nevirapine-containing fixed dose combination in the CHAPAS trial

• Once a day lamivudine and abacavir, and abacavir hypersensitivity in the ARROW trial

Antiretrovirals

• GSK and Pfizer launch joint HIV collaboration

Treatment access

• AIDS and mortality in South Africa

• Punishing success in tackling AIDS: funders retreat could wipe out health gains in HIV affected countries

• FDA approval of generic ARVs

Paediatric care

• HIV, the brain and children

PK and drug interactions

• Reduced etravirine levels after direct switch from efavirenz

• Gemfibrozil significantly reduced by lopinavir/r

Basic science and immunology

• Aging, HIV infection and the immune system

• New neutralising antibodies discovered

• The end of the line for IL-2

Drug resistance

• Rate of accumulation of TAMS slow in patients continuing on failing AZT or d4T containing regimens

Other news

• President Obama announces end to HIV-positive immigration ban in the US

On the web

• BHIVA Autumn Conference and CHIVA Parallel Sessions

• 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention abstracts

• WHO meeting: the impact of ARV treatment on prevention

• JAIDS Supplement: HIV scale-up and global health systems

• Returned to risk: deportation of HIV-positive migrants

• UK patient survey: you, your GP and HIV

• PLoS Medicine – November 2009

PDFs

• Volume 10 Number 11/12 November/December PDF